The Middle East hereditary cancer testing market size was estimated at USD 66.25 million in 2024 and is projected to reach USD 169.10 million by 2033, growing at a CAGR of 11.28% from 2025 to 2033. The market is expanding rapidly, driven by high cancer prevalence, consanguinity, and national precision medicine initiatives. In the UAE, partnerships such as Viafet Genomics with Euformatics are strengthening NGS-based hereditary cancer testing, supported by the National Cancer Control Plan. Qatar, through the Qatar Genome Programme and NCCCR, has pioneered BRCA testing and large-scale genome sequencing, positioning itself as a leader in precision oncology. Kuwait aligns with global hereditary cancer rates (10%) and is advancing genetic services, IVF success, and early cancer detection through KCCC-led initiatives.
The Middle East hereditary cancer testing market is evolving rapidly, driven by high cancer incidence rates, unique demographic structures, and strong government-led precision medicine initiatives. Countries such as the UAE, Qatar, and Kuwait are spearheading regional adoption by embedding hereditary testing into cancer control frameworks, expanding laboratory capabilities, and integrating genomics into public health programs. Collectively, these factors are positioning the region as a fast-growing market for hereditary and predictive oncology diagnostics.
The UAE has emerged as a frontrunner in precision oncology. In 2021, the country reported 5,830 new cancer cases, with a crude incidence rate of 60.5 per 100,000 and an age-standardized rate of 107.8 per 100,000. Breast cancer was the leading malignancy, accounting for 20.3% of all cancers, followed by thyroid (10.6%) and colorectal cancers (9.5%). Emiratis represented 25.6% of cases, while expatriates-who form the majority population-accounted for 74.4%, underscoring the need for inclusive testing strategies. Despite clear hereditary risk, screening uptake remains low-only around 25% for both breast and colorectal cancer. This gap creates strong potential for hereditary testing to complement screening and identify high-risk individuals earlier. Hospitals are adopting NGS-based multi-gene panels, BRCA1/2, PALB2, and Lynch syndrome testing, as well as liquid biopsies. Policy frameworks such as the National Cancer Control Plan (2022-2026) and updated National Cancer Screening Guidelines mandate structured programs, integrate molecular diagnostics, and expand insurance coverage.
The UAE’s ecosystem is also being shaped by private-sector innovation and global partnerships. A notable example is the 2022 collaboration between Viafet Genomics Laboratory in Dubai and Euformatics, aimed at expanding clinical genetics services across the Gulf. Viafet has deployed Euformatics’ OmnomicsNGS bioinformatics platform in its data center to support a wide range of next-generation sequencing (NGS) applications, from whole exome analysis to carrier screening and hereditary cancer testing. The flexibility of the platform to manage both single-patient and multi-patient pipelines, combined with integrated quality control and validation, strengthens confidence in clinical-grade genetic data. By tailoring reporting frameworks and optimizing workflows, the partnership has enhanced Viafet’s capacity to deliver high-quality hereditary and cancer genomics services in the UAE. Together with national-level precision medicine policies, these advancements underscore why the UAE is set to grow at a double-digit CA
GR, positioning it as a cornerstone of precision oncology in the region.
Qatar represents one of the region’s most advanced hereditary cancer testing ecosystems, shaped by its high consanguinity rate of nearly 55%, large family structures, and strong state-backed genomics programs. Breast cancer accounts for 36% of female cancers, with early-onset disease prevalent among Qatari women due to BRCA1/2 mutations and founder effects. The Hereditary Breast and Ovarian Cancer and High-Risk Clinic, launched in 2013 at the National Center for Cancer Care and Research (NCCCR), pioneered regional hereditary testing. By 2016, it had evaluated 697 patients, with 38% testing BRCA-positive, and such cases were strongly linked to young-onset, triple-negative breast cancer. In 2015, in-house CAP-accredited BRCA testing at Hamad Medical Corporation removed cost barriers and increased uptake. National-scale initiatives such as the Qatar Genome Programme and Qatar Biobank have already sequenced more than 29,000 genomes, targeting 100,000 by 2025, and developed tools such as QChipPMv2 for variant detection. Coupled with translational research at Sidra Medicine and QBRI, Qatar has built a globally competitive infrastructure. Furthermore, the launch of a genetic counseling master’s program in 2018 ensures culturally sensitive expertise, positioning Qatar as both a domestic leader and regional model for hereditary cancer testing and precision oncology.
This product will be delivered within 1-3 business days.
The Middle East hereditary cancer testing market is evolving rapidly, driven by high cancer incidence rates, unique demographic structures, and strong government-led precision medicine initiatives. Countries such as the UAE, Qatar, and Kuwait are spearheading regional adoption by embedding hereditary testing into cancer control frameworks, expanding laboratory capabilities, and integrating genomics into public health programs. Collectively, these factors are positioning the region as a fast-growing market for hereditary and predictive oncology diagnostics.
The UAE has emerged as a frontrunner in precision oncology. In 2021, the country reported 5,830 new cancer cases, with a crude incidence rate of 60.5 per 100,000 and an age-standardized rate of 107.8 per 100,000. Breast cancer was the leading malignancy, accounting for 20.3% of all cancers, followed by thyroid (10.6%) and colorectal cancers (9.5%). Emiratis represented 25.6% of cases, while expatriates-who form the majority population-accounted for 74.4%, underscoring the need for inclusive testing strategies. Despite clear hereditary risk, screening uptake remains low-only around 25% for both breast and colorectal cancer. This gap creates strong potential for hereditary testing to complement screening and identify high-risk individuals earlier. Hospitals are adopting NGS-based multi-gene panels, BRCA1/2, PALB2, and Lynch syndrome testing, as well as liquid biopsies. Policy frameworks such as the National Cancer Control Plan (2022-2026) and updated National Cancer Screening Guidelines mandate structured programs, integrate molecular diagnostics, and expand insurance coverage.
The UAE’s ecosystem is also being shaped by private-sector innovation and global partnerships. A notable example is the 2022 collaboration between Viafet Genomics Laboratory in Dubai and Euformatics, aimed at expanding clinical genetics services across the Gulf. Viafet has deployed Euformatics’ OmnomicsNGS bioinformatics platform in its data center to support a wide range of next-generation sequencing (NGS) applications, from whole exome analysis to carrier screening and hereditary cancer testing. The flexibility of the platform to manage both single-patient and multi-patient pipelines, combined with integrated quality control and validation, strengthens confidence in clinical-grade genetic data. By tailoring reporting frameworks and optimizing workflows, the partnership has enhanced Viafet’s capacity to deliver high-quality hereditary and cancer genomics services in the UAE. Together with national-level precision medicine policies, these advancements underscore why the UAE is set to grow at a double-digit CA
GR, positioning it as a cornerstone of precision oncology in the region.
Qatar represents one of the region’s most advanced hereditary cancer testing ecosystems, shaped by its high consanguinity rate of nearly 55%, large family structures, and strong state-backed genomics programs. Breast cancer accounts for 36% of female cancers, with early-onset disease prevalent among Qatari women due to BRCA1/2 mutations and founder effects. The Hereditary Breast and Ovarian Cancer and High-Risk Clinic, launched in 2013 at the National Center for Cancer Care and Research (NCCCR), pioneered regional hereditary testing. By 2016, it had evaluated 697 patients, with 38% testing BRCA-positive, and such cases were strongly linked to young-onset, triple-negative breast cancer. In 2015, in-house CAP-accredited BRCA testing at Hamad Medical Corporation removed cost barriers and increased uptake. National-scale initiatives such as the Qatar Genome Programme and Qatar Biobank have already sequenced more than 29,000 genomes, targeting 100,000 by 2025, and developed tools such as QChipPMv2 for variant detection. Coupled with translational research at Sidra Medicine and QBRI, Qatar has built a globally competitive infrastructure. Furthermore, the launch of a genetic counseling master’s program in 2018 ensures culturally sensitive expertise, positioning Qatar as both a domestic leader and regional model for hereditary cancer testing and precision oncology.
Middle East Hereditary Cancer Testing Market Report Segmentation
This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East hereditary cancer testing market report on the basis of cancer, test type, technology, end use, and country:Cancer Outlook (Revenue, USD Million, 2021-2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Ovarian Cancer
- Prostate Cancer
- Stomach/Gastric Cancer
- Melanoma
- Sarcoma
- Uterine Cancer
- Pancreatic Cancer
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Cytogenetic
- Biochemical
- Molecular Testing
Test Type Outlook (Revenue, USD Million, 2021-2033)
- Predictive Testing
- Diagnostic Testing
End Use Outlook (Revenue, USD Million, 2021-2033)
- Diagnostic Centers
- Hospitals
- Clinics
- Country Outlook (Revenue in USD Million, 2021-2033)
- Middle East
- UAE
- Kuwait
- Oman
- Qatar
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. ME Hereditary Cancer Testing Market Variables, Trends & Scope
Chapter 4. ME Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis
Chapter 5. ME Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis
Chapter 6. ME Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis
Chapter 7. ME Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis
Chapter 8. ME Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East Hereditary Cancer Testing market report include:- Myriad Genetics
- Invitae Corporation
- Bio-Rad Laboratories
- CSL Ltd
- Qiagen NV
- Danaher Corporation
- Thermo Fisher Scientific
- Abbott Laboratories
- EUROFINS SCIENTIFIC
- F. HOFFMANN-LA ROCHE LTD
- Illumina, Inc.
